Investing
Biotechnology Value Fund discloses stake in ARAV / Aravive

Published:
Last Updated:
Biotechnology Value Fund L P has filed a 13G form with the SEC disclosing ownership of 6,109,058 shares of Aravive Inc (ARAV). This represents 9.99% of the company.
What are other large shareholders doing?
Armistice Capital, Llc holds 1,316,129 shares representing 2.20% ownership of the company. In it’s prior filing, the firm reported owning 934,975 shares, representing an increase of 28.96%. The firm decreased its portfolio allocation in ARAV by 35.02% over the last quarter.
Artal Group S.A. holds 1,311,291 shares representing 2.19% ownership of the company. No change in the last quarter.
New Leaf Venture Partners, L.L.C. holds 946,423 shares representing 1.58% ownership of the company. No change in the last quarter.
Vanguard Group Inc holds 457,220 shares representing 0.76% ownership of the company. No change in the last quarter.
Renaissance Technologies Llc holds 374,945 shares representing 0.63% ownership of the company. In it’s prior filing, the firm reported owning 277,829 shares, representing an increase of 25.90%. The firm decreased its portfolio allocation in ARAV by 30.36% over the last quarter.
What is the overall institutional sentiment?
There are 57 funds or institutions reporting positions in Aravive Inc. This is a decrease of 6 owner(s) or 9.52%.
Average portfolio weight of all funds dedicated to Aravive Inc is 0.0132%, a decrease of 31.3867%. Total shares owned by institutions increased in the last three months by 4.30% to 5,598,986 shares.
Based on this information, institutional sentiment is bearish.
This article originally appeared on Fintel
Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.
Here’s how it works:
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.